Methods and materials for identifying and treating membranous nephropathy
US-2024353404-A1 · Oct 24, 2024 · US
US9662405B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9662405-B2 |
| Application number | US-201514879936-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 9, 2015 |
| Priority date | Apr 26, 2012 |
| Publication date | May 30, 2017 |
| Grant date | May 30, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding.
Opening claim text (preview).
The invention claimed is: 1. A method of treating a subject who has been diagnosed as having cancer comprising cancer cells that express guanylyl cyclase C (GCC), the method comprising administering to said subject a therapeutically effective amount of T cells that express a chimeric antigen receptor comprising a light chain variable region and a heavy chain variable region of an anti-GCC antibody molecule, the chimeric antigen receptor comprising: heavy chain variable region Amino Acid Sequence SEQ ID NO:3 from anti-GCC antibody MS20, and light chain variable region Amino Acid Sequence SEQ ID NO:4 from anti-GCC antibody MS20; wherein the chimeric antigen receptor binds to human GCC. 2. The method of claim 1 , wherein the cancer is metastatic colorectal cancer, primary and/or metastatic esophageal cancer, or primary and/or metastatic stomach cancer. 3. The method of claim 1 , wherein the cancer is metastatic colorectal cancer. 4. The method of claim 1 , wherein the cancer is primary and/or metastatic esophageal. 5. The method of claim 1 , wherein the cancer is primary and/or metastatic stomach cancer.
against enzymes · CPC title
for enzymes or isoenzymes · CPC title
Human Necessities · mapped topic
Single chain antibody (scFv) · CPC title
Physics · mapped topic
Related publications grouped by family.
Answers are generated from the same data shown on this page.